General
Preferred name
IBREXAFUNGERP
Synonyms
SCY-078 ()
Ibrexafungerp (citrate) ()
MK 3118 (citrate) ()
SCY-078 (citrate) ()
MK 3118 ()
MK-3118 FREE BASE ()
MK3118 ()
MK-3118 ()
Brexafemme ()
SCY-078 citrate ()
IBREXAFUNGERP CITRATE ()
P&D ID
PD058025
CAS
1207753-03-4
1965291-08-0
Tags
available
drug
Approved by
FDA
First approval
2021
Drug indication
Fungal infection
Invasive candidiasis
Aspergillosis
Vulvovaginal Candidiasis
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
3454
DESCRIPTION
Ibrexafungerp (MK 3118) is an orally active ??-1,3-glucan synthase inhibitor with antifungal activity, disrupting fungal cell wall integrity, used in fungal infection research.
DESCRIPTION
Ibrexafungerp citrate (MK 3118 citrate) is an orally active ¦Â-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp citrate is an investigational agent for the treatment of Candida and Aspergillus infections[1].
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
8
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
MedChem Express Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
50
Molecular Weight
729.52
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
7
Aromatic Ring Count
2
cLogP
8.62
TPSA
125.38
Fraction CSP3
0.77
Chiral centers
12.0
Largest ring
6.0
QED
0.26
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Fungal
Pathway
Anti-infection
Source data

